

Shuiying Hu

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7088378/shuiying-hu-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

71
papers

2,845
citations

31
h-index

53
g-index

78
ext. papers

3,315
ext. citations

6.8
avg, IF

4.72
L-index

#	Paper	IF	Citations
71	Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 1161-70	12.9	317
70	Interaction of imatinib with human organic ion carriers. <i>Clinical Cancer Research</i> , 2008 , 14, 3141-8	12.9	176
69	Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 4688-93	5.6	171
68	Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. <i>Clinical Cancer Research</i> , 2007 , 13, 1341-9	12.9	141
67	Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. <i>Blood</i> , 2013 , 122, 3607-15	2.2	140
66	Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. <i>International Journal of Cancer</i> , 2006 , 119, 2322-9	7.5	140
65	Pharmacogenetic pathway analysis of docetaxel elimination. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 85, 155-63	6.1	135
64	Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. <i>Clinical Cancer Research</i> , 2009 , 15, 6062-9	12.9	132
63	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. <i>Clinical Cancer Research</i> , 2013 , 19, 1458-66	12.9	109
62	High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 5265-9	5.6	101
61	A phosphotyrosine switch regulates organic cation transporters. <i>Nature Communications</i> , 2016 , 7, 10880	17.4	74
60	Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. <i>Clinical Cancer Research</i> , 2012 , 18, 4433-40	12.9	70
59	Phosphatidylinositol 3-kinase/Akt positively regulates Fas (CD95)-mediated apoptosis in epidermal CL41 cells. <i>Journal of Immunology</i> , 2006 , 176, 6785-93	5.3	57
58	Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. <i>Clinical Cancer Research</i> , 2013 , 19, 236-46	12.9	56
57	Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 5231-6	11.5	51
56	Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy. <i>Nature Communications</i> , 2020 , 11, 972	17.4	49
55	Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b. <i>Cancer Research</i> , 2015 , 75, 2729-36	10.1	46

54	Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 585-92	6.1	46
53	Inhibition of OCTN2-mediated transport of carnitine by etoposide. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 921-9	6.1	46
52	Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). <i>Clinical Cancer Research</i> , 2014 , 20, 985-94	12.9	45
51	Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 893-905	9.7	45
50	Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1110-20	6.1	40
49	Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. <i>British Journal of Cancer</i> , 2014 , 110, 894-8	8.7	38
48	Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1537-44	6.1	38
47	Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 98-104	5.6	38
46	OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. <i>Journal of Clinical Investigation</i> , 2018 , 128, 816-825	15.9	38
45	Silica-induced apoptosis in alveolar macrophages: evidence of in vivo thiol depletion and the activation of mitochondrial pathway. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2006 , 69, 1261-84	3.2	37
44	Influence of drug formulation on OATP1B-mediated transport of paclitaxel. <i>Cancer Research</i> , 2014 , 74, 3137-45	10.1	36
43	Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy. <i>Clinical Cancer Research</i> , 2019 , 25, 6295-6301	12.9	35
42	Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. <i>Clinical Cancer Research</i> , 2013 , 19, 4359-4370	12.9	34
41	Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death. <i>Cancer Research</i> , 2016 , 76, 117-26	10.1	33
40	OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. <i>Cancer Research</i> , 2017 , 77, 2102-2111	10.1	30
39	Evaluation of artemisinin for the treatment of acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 1231-43	3.5	30
38	Pharmacokinetic considerations for new targeted therapies. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 85, 208-11	6.1	26
37	Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. <i>Journal of Clinical Investigation</i> , 2020 , 130, 4601-4606	15.9	22

36	OATP1B1 polymorphism as a determinant of erythromycin disposition. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 642-50	6.1	21
35	Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 99, 651-60	6.1	19
34	Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy. <i>Materials Science and Engineering C</i> , 2019 , 102, 113-123	8.3	17
33	Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 227-237	6.1	16
32	Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2020 , 48, 419-425	4	15
31	Role of mitochondria in silica-induced apoptosis of alveolar macrophages: inhibition of apoptosis by rhodamine 6G and N-acetyl-L-cysteine. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2007 , 70, 1403-15	3.2	14
30	Murine Pharmacokinetic Studies. <i>Bio-protocol</i> , 2018 , 8,	0.9	11
29	Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. <i>Cancers</i> , 2021 , 13,	6.6	11
28	Drug transporters and anthracycline-induced cardiotoxicity. <i>Pharmacogenomics</i> , 2018 , 19, 883-888	2.6	10
27	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. <i>Nature Communications</i> , 2019 , 10, 2189	17.4	9
26	Role for Drug Transporters in Chemotherapy-Induced Peripheral Neuropathy. <i>Clinical and Translational Science</i> , 2021 , 14, 460-467	4.9	9
25	Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018 , 1090, 43-51	3.2	8
24	Interaction Between Sex and Organic Anion-Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in Mice. <i>Clinical and Translational Science</i> , 2019 , 12, 400-407	4.9	7
23	Targeting OCT3 attenuates doxorubicin-induced cardiac injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	7
22	Role of transporters in toxicity induced by anticancer drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 493-506	5.5	6
21	Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice. <i>Pharmacology Research and Perspectives</i> , 2019 , 7, e00534	3.1	6
20	DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. <i>Clinical and Translational Science</i> , 2021 , 14, 137-142	4.9	6
19	Strategies to Reduce Solute Carrier-Mediated Toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 799-802	6.1	4

18	Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2020 , 1	2.9	4
17	Regulation of OATP1B1 Function by Tyrosine Kinase-mediated Phosphorylation. <i>Clinical Cancer Research</i> , 2021 , 27, 4301-4310	12.9	4
16	Predicting Paclitaxel Disposition in Humans With Whole-Body Physiologically-Based Pharmacokinetic Modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 931-939	4.5	3
15	A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS12125-TPS12125	2.2	3
14	Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1. <i>Frontiers in Pharmacology</i> , 2021 , 12, 644342	5.6	3
13	Abstract 14035: Renal Tubular Secretion and Cardiac Distribution of Dofetilide is Dependent on MATE1 Function. <i>Circulation</i> , 2020 , 142,	16.7	1
12	A phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS12128-TPS12128	2.2	1
11	Targeting drug transporters to prevent chemotherapy-induced peripheral neuropathy. <i>Molecular and Cellular Oncology</i> , 2021 , 8, 1838863	1.2	1
10	Genetic and Pharmacological Inhibition of OCT2 Protects Rats against Oxaliplatin-Induced Peripheral Neuropathy. <i>FASEB Journal</i> , 2019 , 33, 813.9	0.9	1
9	Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1168, 122591	3.2	1
8	Contribution of membrane transporters to chemotherapy-induced cardiotoxicity. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021 ,	3.1	1
7	Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation. <i>Molecules</i> , 2021 , 26,	4.8	1
6	Development and validation of a UPLC-MS/MS analytical method for dofetilide in mouse plasma and urine, and its application to pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 172, 183-188	3.5	0
5	Role of transporters and S100A8/A9 in paclitaxel-induced peripheral neuropathy. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	
4	Preclinical Evaluation of Sorafenib in Combination with Cytarabine and Clofarabine in Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007 , 110, 4202-4202	2.2	
3	Epigenetic Regulation of OCTN1-mediated Cytarabine Transport in Acute Myeloid Leukemia. <i>FASEB Journal</i> , 2019 , 33, 675.2	0.9	
2	Role of OATP2B1 in Drug Absorption and Drug-Drug Interactions. <i>FASEB Journal</i> , 2019 , 33, 507.7	0.9	
1	TAK1 is a Regulator of Sorafenib-induced Keratinocyte Toxicity. <i>FASEB Journal</i> , 2013 , 27, 657.1	0.9	

